Pipeline & Programs
Pipeline
Advancing towards tailored treatments for complex neurological disorders
The Alcyone pipeline features two candidates in or approaching clinical development and a number of additional candidates under preclinical development. Our streamlined approach facilitates application of technical and disease-area expertise for rapid progression of candidates to the clinic.
| PLATFORM | Candidate | Indication | Concept | Preclinical | IND-Enabling |
CLINICAL PHASES
| Patient Prevalance | ||
|---|---|---|---|---|---|---|---|---|---|
|
ACTX-401 | IGHMBP2-related disorders | < 1,000 | ||||||
| Undisclosed | > 10,000 | ||||||||
|
ACTX-101 | Rett syndrome | > 25,000 | ||||||
| Other x-linked dominant disorders | > 10,000 | ||||||||
|
Undisclosed | > 15,000 | |||||||
| Undisclosed | > 15,000 | ||||||||
|
Undisclosed | > 15,000 | |||||||
| Undisclosed | > 30,000 | ||||||||
